XML 19 R2.htm IDEA: XBRL DOCUMENT v3.23.2
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Jun. 30, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 152,585 $ 155,700
Short-term investments 183,131 266,308
Accounts receivable, net ($19,951 and $12,088 from related parties) 25,599 16,299
Inventories 41,179 40,436
Prepaid expenses and other current assets 8,863 14,083
Total current assets 411,357 492,826
Restricted time deposits 2,072 2,072
Long-term investments 0 4,348
Property and equipment, net 16,829 20,605
Equity method investment in unconsolidated variable interest entity 6,112 5,061
Operating lease right-of-use assets 74,404 79,893
Other assets 4,353 5,282
Total assets 515,127 610,087
Current liabilities:    
Accounts payable ($4,578 and $0 to a related party) 12,802 30,758
Accrued and other current liabilities ($25,229 and $63,886 to a related party) 162,769 219,773
Deferred revenue ($3,485 and $9,259 to related parties) 7,490 12,739
Operating lease liabilities, current 11,011 10,292
Total current liabilities 194,072 273,562
Product development obligations 17,365 16,917
Deferred revenue, net of current 165,416 185,722
Operating lease liabilities, non-current 73,813 79,593
Senior secured term loan facilities, non-current 71,408 0
Liability related to sale of future revenues, non-current 48,399 49,333
Other long-term liabilities ($577 and $0 to a related party) 4,961 6,440
Total liabilities 575,434 611,567
Commitments and Contingencies (Note 12)
Redeemable non-controlling interests 21,480 0
Stockholders' deficit:    
Preferred stock, $0.01 par value; 125,000 shares authorized; no shares issued and outstanding at June 30, 2023 and December 31, 2022
Common stock, $0.01 par value; 225,000 shares authorized at June 30, 2023 and December 31, 2022; 98,204 and 94,166 shares issued and outstanding at June 30, 2023 and December 31, 2022 982 942
Additional paid-in capital 1,625,067 1,541,019
Accumulated other comprehensive loss (6,250) (5,720)
Accumulated deficit (1,722,073) (1,557,688)
Total stockholders' deficit attributable to FibroGen (102,274) (21,447)
Nonredeemable non-controlling interests 20,487 19,967
Total deficit (81,787) (1,480)
Total liabilities, redeemable non-controlling interests and deficit $ 515,127 $ 610,087